Galecto Inc. (GLTO): Price and Financial Metrics
GLTO Price/Volume Stats
| Current price | $0.72 | 52-week high | $3.70 |
| Prev. close | $0.73 | 52-week low | $0.54 |
| Day low | $0.69 | Volume | 537,200 |
| Day high | $0.75 | Avg. volume | 285,401 |
| 50-day MA | $1.33 | Dividend yield | N/A |
| 200-day MA | $1.91 | Market Cap | 19.51M |
GLTO Stock Price Chart Interactive Chart >
Galecto Inc. (GLTO) Company Bio
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.
Latest GLTO News From Around the Web
Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.
Spotify downgraded, Tractor Supply upgraded: Wall Street's top analyst callsToday's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning! |
Galecto Announces Plans to Explore Strategic AlternativesBOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Galecto |
Galecto to Present at Investor Conferences in SeptemberBOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings. H.C. Wainwright 25th Annual Global Investment ConferenceDate |
OrbiMed Advisors LLC Reduces Stake in Galecto IncFirm real-time pick highlight |
GLTO Price Returns
| 1-mo | 22.03% |
| 3-mo | N/A |
| 6-mo | -66.51% |
| 1-year | -61.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -37.39% |
| 2022 | -62.05% |
| 2021 | -75.78% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...